ArticleThe journal of prevention of Alzheimer's disease2025
Expert opinion on Centiloid thresholds suitable for initiating anti-amyloid therapy. Summary of discussion at the 2024 spring Alzheimer's Association Research Roundtable.
Article in The journal of prevention of Alzheimer's disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Do amyloid trajectories reach a ceiling? Evidence from iterative approximation and simulation.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Relative importance of blood-based biomarkers for Alzheimer's disease-specific neurodegeneration and cognitive decline.The journal of prevention of Alzheimer's disease · 2026Article
- The Dementias Platform UK PET/MR harmonisation and test-retest study: assessment of PET repeatability and reproducibility across the national network.European journal of nuclear medicine and molecular imaging · 2026Article
- The Centiloid Scale in Amyloid PET Imaging: Current Role in Alzheimer's Disease Diagnosis, Treatment Planning, and Monitoring During Anti-Amyloid Therapy: A Clinical Perspective.Diagnostics (Basel, Switzerland) · 2026Review
- Thalamic nuclei insights into Alzheimer's disease.bioRxiv : the preprint server for biology · 2026Article
- Precision pathways: optimising amyloid PET for sustainable Alzheimer's disease care.Journal of neurology · 2026Review
- Clinical amyloid and tau positron emission tomography imaging in Alzheimer's disease: image interpretation in the era of anti-amyloid therapies.Current opinion in neurology · 2026Review
- Locus coeruleus degeneration is associated with cortical tau deposition and cognitive decline in older adults at familial risk of Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Predicting onset of symptomatic Alzheimer's disease with plasma p-tau217 clocks.Nature medicine · 2026Article
- AI-enhanced Centiloid quantification of amyloid PET images.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Neighborhood socioeconomic deprivation is associated with worse cognitive performance and in vivo amyloid accumulation.NPJ dementia · 2026Article
- Phenotypic variability in early-onset dementia segregating with a novel APP (p.I718M) variant.Alzheimer's research & therapy · 2025Article
- Concordance between amyloid PET and CSF biomarkers in clinical setting: a cross-platform comparison and in-depth analysis of discordant cases.Scientific reports · 2025Article
- Concordance Between Amyloid-PET Quantification and Real-World Visual Reads.JAMA neurology · 2025Article
- Revisiting Centiloids using AI.Research square · 2025Article
- Discrepancies between CSF biomarker and PET determinations of elevated brain amyloid and their prognostic significance.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Elapsed time changes of the brain radiopharmaceutical accumulation of the amyloid PET examination usingAnnals of nuclear medicine · 2025Article
- A brief history of Aβ imaging.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Review
- 2024 Alzheimer's Association criteria for Alzheimer's disease diagnosis are usually anchored to both plaques and tangles, not Aβ alone.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Inter-software variability of Centiloid quantification in amyloid PET: A head-to-head comparison of five software platforms.Alzheimer's & dementia (Amsterdam, Netherlands)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A 24-30 Centiloid (CL) threshold was collectively considered by a group of global dementia experts as a practical and implementable cut-off for anti-amyloid therapy intervention, in Alzheimer's disease patients who have been diagnosed at the mild cognitive impairment or mild dementia stage of their disease. Though additional validation is needed, knowledge of this threshold would be valuable to those involved in diagnosing and treating patients in the new AD care pathways, as well as entry into clinical trials. Therapy monitoring to determine future treatment response and assess amyloid clearance can be accomplished with amyloid PET with some technical details still to be elucidated.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.